Huntington’s disease (HD) is a progressive neurodegenerative disorder characterized by motor dysfunction, cognitive decline, and psychiatric disturbances. It is caused by the abnormal expansion of cytosine-adenine-guanine triplet repeats in the HTT gene, leading to the production of mutant huntingtin (mHTT) protein. This protein contributes to neuronal dysfunction and cell death, particularly in the striatum and cortex. The review examines recent research focused on identifying and assessing potential biomarkers of HD, emphasizing the use of peripheral fluids and tissues as sources of biomaterials. Among the reviewed biomarkers, neurofilament light chain and mHTT emerge as robust indicators of disease progression, while combined biofluid and imaging biomarkers show promise for improving prognostic accuracy. These biomarkers offer insights into key pathological features of HD, such as oxidative damage, mitochondrial impairments, and persistent inflammatory responses. The incorporation of diverse biomarkers, including those from peripheral fluids and tissues, holds great promise for improving the diagnosis and management of HD. A well-defined and validated biomarker panel could significantly enhance clinical outcomes by facilitating early detection, monitoring disease progression, and evaluating therapeutic efficacy. Ultimately, this progress could accelerate drug development and lead to more effective treatment strategies for HD.
HarjesP, WankerEE. The hunt for huntingtin function: Interaction partners tell many different stories. Trends Biochem Sci, 2003; 28(8):425–433; doi: 10.1016/S0968-0004(03)00168-3
4.
SmithDK, HeM, ZhangC-L, et al.The therapeutic potential of cell identity reprogramming for the treatment of aging-related neurodegenerative disorders. Prog Neurobiol, 2017; 157(1):212–229; doi: 10.1016/j.pneurobio.2016.01.006
5.
FolsteinSE. The psychopathology of Huntington’s disease. Res Publ Assoc Res Nerv Ment Dis, 1991; 69(5):181–191.
6.
RossCA, AylwardEH, WildEJ, et al.Huntington disease: Natural history, biomarkers and prospects for therapeutics. Nat Rev Neurol, 2014; 10(4):204–216; doi: 10.1038/nrneurol.2014.24
KitaH, KitaiST. Glutamate decarboxylase immunoreactive neurons in rat neostriatum: Their morphological types and populations. Brain Res, 1988; 447(2):346–352; doi: 10.1016/0006-8993(88)91138-9
9.
GraybielAM. Neurotransmitters and neuromodulators in the basal ganglia. Trends Neurosci, 1990; 13(7):244–254; doi: 10.1016/0166-2236(90)90104-i
10.
TepperJM, WilsonCJ, KoósT. Feedforward and feedback inhibition in neostriatal GABAergic spiny neurons. Brain Res Rev, 2008; 58(2):272–281; doi: 10.1016/j.brainresrev.2007.10.008
11.
PisaniA, BernardiG, DingJ, et al.Re-emergence of striatal cholinergic interneurons in movement disorders. Trends Neurosci, 2007; 30(10):545–553; doi: 10.1016/j.tins.2007.07.008
12.
MontoyaA, PriceBH, MenearM, et al.Brain imaging and cognitive dysfunctions in Huntington’s disease. J Psychiatry Neurosci, 2006; 31(1):21–29.
13.
PaulsenJS, LangbehnDR, StoutJC, et al.; Predict-HD Investigators and Coordinators of the Huntington Study Group. Detection of Huntington’s disease decades before diagnosis: The Predict-HD study. J Neurol Neurosurg Psychiatry, 2008; 79(8):874–880; doi: 10.1136/jnnp.2007.128728
14.
ZuccatoC, ValenzaM, CattaneoE. Molecular mechanisms and potential therapeutical targets in Huntington’s disease. Physiol Rev, 2010; 90(3):905–981; doi: 10.1152/physrev.00041.2009
15.
JurcauA. Insights into the pathogenesis of neurodegenerative diseases: Focus on mitochondrial dysfunction and oxidative stress. Int J Mol Sci, 2021; 22(21):11847; doi: 10.3390/ijms222111847
16.
LeitesEP, MoraisVA. Mitochondrial quality control pathways: PINK1 acts as a gatekeeper. Biochem Biophys Res Commun, 2018; 500(1):45–50; doi: 10.1016/j.bbrc.2017.06.096
17.
NichollsDG. Brain mitochondrial calcium transport: Origins of the set-point concept and its application to physiology and pathology. Neurochem Int, 2017; 109:5–12; doi: 10.1016/j.neuint.2016.12.018
18.
AngelovaPR, AbramovAY. Role of mitochondrial ROS in the brain: From physiology to neurodegeneration. FEBS Lett, 2018; 592(5):692–702; doi: 10.1002/1873-3468.12964
19.
MoilyNS, OrmsbyAR, StojilovicA, et al.Transcriptional profiles for distinct aggregation states of mutant Huntingtin exon 1 protein unmask new Huntington’s disease pathways. Mol Cell Neurosci, 2017; 83:103–112; doi: 10.1016/j.mcn.2017.07.004
20.
TaoX, FinkbeinerS, ArnoldDB, et al.Ca2+ influx regulates BDNF transcription by a CREB family transcription factor-dependent mechanism. Neuron, 1998; 20(4):709–726; doi: 10.1016/s0896-6273(00)81010-7
21.
AltarCA, CaiN, BlivenT, et al.Anterograde transport of brain-derived neurotrophic factor and its role in the brain. Nature, 1997; 389(6653):856–860; doi: 10.1038/39885
22.
Pérez-NavarroE, CanalsJM, GinésS, et al.Cellular and molecular mechanisms involved in the selective vulnerability of striatal projection neurons in Huntington’s disease. Histol Histopathol, 2006; 21(11):1217–1232; doi: 10.14670/HH-21.1217
23.
FuscoFR, PaldinoE. Role of phosphodiesterases in Huntington’s disease. Adv Neurobiol, 2017; 17:285–304; doi: 10.1007/978-3-319-58811-7_11
24.
KnottEP, AssiM, RaoSNR, et al.Phosphodiesterase inhibitors as a therapeutic approach to neuroprotection and repair. Int J Mol Sci, 2017; 18(4):696; doi: 10.3390/ijms18040696
25.
CardinaleA, FuscoFR. Inhibition of phosphodiesterases as a strategy to achieve neuroprotection in Huntington’s disease. CNS Neurosci Ther, 2018; 24(4):319–328; doi: 10.1111/cns.12834
26.
StephensonJ, NutmaE, van der ValkP, et al.Inflammation in CNS neurodegenerative diseases. Immunology, 2018; 154(2):204–219; doi: 10.1111/imm.12922
27.
Gómez-RíoM, CaballeroMM, Górriz SáezJM, et al.Diagnosis of neurodegenerative diseases: The clinical approach. Curr Alzheimer Res, 2016; 13(5):469–474; doi: 10.2174/1567205013666151116141603
28.
LewczukP, RiedererP, O’BryantSE, et al.; Members of the WFSBP Task Force Working on this Topic: Peter Riederer, Carla Gallo, Dimitrios Kapogiannis, Andrea Lopez Mato, Florence Thibaut. Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the consensus of the task force on biological markers in psychiatry of the World Federation of Societies of Biological Psychiatry. World J Biol Psychiatry, 2018; 19(4):244–328; doi: 10.1080/15622975.2017.1375556
29.
LaterzaOF, HendricksonRC, WagnerJA. Molecular biomarkers. Drug Information J, 2007; 41(5):573–585; doi: 10.1177/009286150704100504
30.
RossCA, ShoulsonI. Huntington disease: Pathogenesis, biomarkers, and approaches to experimental therapeutics. Parkinsonism Relat Disord, 2009; 15(Suppl 3):S135–S138; doi: 10.1016/S1353-8020(09)70800-4
AndreR, ScahillRI, HaiderS, et al.Biomarker development for Huntington’s disease. Drug Discov Today, 2014; 19(7):972–979; doi: 10.1016/j.drudis.2014.03.002
33.
ThakkarA, HuangX, WangJ, et al.Elevated serum IgA at onset of type 1 diabetes in children. Pediatr Diabetes, 2024; 2024:7284088; doi: 10.1155/2024/7284088
34.
TabriziSJ, FlowerMD, RossCA, et al.Huntington disease: New insights into molecular pathogenesis and therapeutic opportunities. Nat Rev Neurol, 2020; 16(10):529–546; doi: 10.1038/s41582-020-0389-4
WildEJ, BoggioR, LangbehnD, et al.Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington’s disease patients. J Clin Invest, 2015; 125(5):1979–1986; doi: 10.1172/JCI80743
37.
FodaleV, BoggioR, DaldinM, et al.Validation of ultrasensitive mutant Huntingtin detection in human cerebrospinal fluid by single molecule counting immunoassay. J Huntingtons Dis, 2017; 6(4):349–361; doi: 10.3233/JHD-170269
38.
ByrneLM, RodriguesFB, JohnsonEB, et al.Evaluation of mutant huntingtin and neurofilament proteins as potential markers in Huntington’s disease. Sci Transl Med, 2018; 10(458):eaat7108; doi: 10.1126/scitranslmed.aat7108
39.
ByrneLM, RodriguesFB, BlennowK, et al.Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington’s disease: A retrospective cohort analysis. Lancet Neurol, 2017; 16(8):601–609; doi: 10.1016/S1474-4422(17)30124-2
40.
HoffmanPN, LasekRJ. The slow component of axonal transport. Identification of major structural polypeptides of the axon and their generality among mammalian neurons. J Cell Biol, 1975; 66(2):351–366; doi: 10.1083/jcb.66.2.351
41.
ShahimP, TegnerY, GustafssonB, et al.Neurochemical aftermath of repetitive mild traumatic brain injury. JAMA Neurol, 2016; 73(11):1308–1315; doi: 10.1001/jamaneurol.2016.2038
42.
JarosińskaOD, RüdigerSGD. Molecular strategies to target protein aggregation in Huntington’s disease. Front Mol Biosci, 2021; 8:769184; doi: 10.3389/fmolb.2021.769184
43.
RossCA, TabriziSJ. Huntington’s disease: From molecular pathogenesis to clinical treatment. Lancet Neurol, 2011; 10(1):83–98; doi: 10.1016/S1474-4422(10)70245-3
44.
TafrihiM, HasheminasabE. MiRNAs: Biology, biogenesis, their web-based tools, and databases. Microrna, 2019; 8(1):4–27; doi: 10.2174/2211536607666180827111633
45.
SoldatiC, BithellA, JohnstonC, et al.Dysregulation of REST-regulated coding and non-coding RNAs in a cellular model of Huntington’s disease. J Neurochem, 2013; 124(3):418–430; doi: 10.1111/jnc.12090
46.
JohnsonR, BuckleyNJ. Gene dysregulation in Huntington’s disease: REST, MicroRNAs and beyond. Neuromolecular Med, 2009; 11(3):183–199; doi: 10.1007/s12017-009-8063-4
47.
EhrnhoeferDE, ButlandSL, PouladiMA, et al.Mouse models of Huntington disease: Variations on a theme. Dis Model Mech, 2009; 2(3–4):123–129; doi: 10.1242/dmm.002451
48.
LangfelderP, GaoF, WangN, et al.MicroRNA signatures of endogenous Huntingtin CAG repeat expansion in mice. PLoS One, 2018; 13(1):e0190550; doi: 10.1371/journal.pone.0190550
49.
Noren HootenN, FitzpatrickM, WoodWH, et al.Age-related changes in microRNA levels in serum. Aging (Albany NY), 2013; 5(10):725–740; doi: 10.18632/aging.100603
50.
PerluigiM, PoonHF, MaragosW, et al.Proteomic analysis of protein expression and oxidative modification in r6/2 transgenic mice: A model of Huntington disease. Mol Cell Proteomics, 2005; 4(12):1849–1861; doi: 10.1074/mcp.M500090-MCP200
51.
SayreLM, PerryG, SmithMA. Oxidative stress and neurotoxicity. Chem Res Toxicol, 2008; 21(1):172–188; doi: 10.1021/tx700210j
52.
CiancarelliI, Di MassimoC, De AmicisD, et al.Evidence of redox unbalance in post-acute ischemic stroke patients. Curr Neurovasc Res, 2012; 9(2):85–90; doi: 10.2174/156720212800410885
53.
StackEC, MatsonWR, FerranteRJ. Evidence of oxidant damage in Huntington’s disease: Translational strategies using antioxidants. Ann N Y Acad Sci, 2008; 1147:79–92; doi: 10.1196/annals.1427.008
54.
SassoneJ, ColciagoC, CislaghiG, et al.Huntington’s disease: The current state of research with peripheral tissues. Exp Neurol, 2009; 219(2):385–397; doi: 10.1016/j.expneurol.2009.05.012
55.
LongJD, MatsonWR, JuhlAR, et al.; PREDICT-HD Investigators and Coordinators of the Huntington Study Group. 8OHdG as a marker for Huntington disease progression. Neurobiol Dis, 2012; 46(3):625–634; doi: 10.1016/j.nbd.2012.02.012
56.
PolidoriMC, MecocciP, BrowneSE, et al.Oxidative damage to mitochondrial DNA in Huntington’s disease parietal cortex. Neurosci Lett, 1999; 272(1):53–56; doi: 10.1016/s0304-3940(99)00578-9
57.
HerschSM, GevorkianS, MarderK, et al.Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2’dG. Neurology, 2006; 66(2):250–252; doi: 10.1212/01.wnl.0000194318.74946.b6
58.
BjörkqvistM, WildEJ, ThieleJ, et al.A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington’s disease. J Exp Med, 2008; 205(8):1869–1877; doi: 10.1084/jem.20080178
59.
DuG, DongW, YangQ, et al.Altered gut microbiota related to inflammatory responses in patients with Huntington’s disease. Front Immunol, 2020; 11:603594; doi: 10.3389/fimmu.2020.603594
60.
WildE, MagnussonA, LahiriN, et al.Abnormal peripheral chemokine profile in Huntington’s disease. PLoS Curr, 2011; 3:RRN1231; doi: 10.1371/currents.RRN1231
61.
PhelpsME. Positron emission tomography provides molecular imaging of biological processes. Proc Natl Acad Sci U S A, 2000; 97(16):9226–9233; doi: 10.1073/pnas.97.16.9226
62.
HuH, McCawEA, HebbALO, et al.Mutant huntingtin affects the rate of transcription of striatum-specific isoforms of phosphodiesterase 10A. Eur J Neurosci, 2004; 20(12):3351–3363; doi: 10.1111/j.1460-9568.2004.03796.x
63.
HebbALO, RobertsonHA, Denovan-WrightEM. Striatal phosphodiesterase mRNA and protein levels are reduced in Huntington’s disease transgenic mice prior to the onset of motor symptoms. Neuroscience, 2004; 123(4):967–981; doi: 10.1016/j.neuroscience.2003.11.009
64.
CurrieS, HoggardN, CravenIJ, et al.Understanding MRI: Basic MR physics for physicians. Postgrad Med J, 2013; 89(1050):209–223; doi: 10.1136/postgradmedj-2012-131342
HarrisGJ, PearlsonGD, PeyserCE, et al.Putamen volume reduction on magnetic resonance imaging exceeds caudate changes in mild Huntington’s disease. Ann Neurol, 1992; 31(1):69–75; doi: 10.1002/ana.410310113
68.
RosasHD, GoodmanJ, ChenYI, et al.Striatal volume loss in HD as measured by MRI and the influence of CAG repeat. Neurology, 2001; 57(6):1025–1028; doi: 10.1212/wnl.57.6.1025
69.
FoxMD, RaichleME. Spontaneous fluctuations in brain activity observed with functional magnetic resonance imaging. Nat Rev Neurosci, 2007; 8(9):700–711; doi: 10.1038/nrn2201
70.
AylwardEH, CodoriAM, BartaPE, et al.Basal ganglia volume and proximity to onset in presymptomatic Huntington disease. Arch Neurol, 1996; 53(12):1293–1296; doi: 10.1001/archneur.1996.00550120105023
71.
AylwardEH, LiQ, StineOC, et al.Longitudinal change in basal ganglia volume in patients with Huntington’s disease. Neurology, 1997; 48(2):394–399; doi: 10.1212/wnl.48.2.394
72.
HarrisGJ, AylwardEH, PeyserCE, et al.Single photon emission computed tomographic blood flow and magnetic resonance volume imaging of basal ganglia in Huntington’s disease. Arch Neurol, 1996; 53(4):316–324; doi: 10.1001/archneur.1996.00550040044013
73.
TabriziSJ, LangbehnDR, LeavittBR, et al.; TRACK-HD investigators. Biological and clinical manifestations of Huntington’s disease in the longitudinal TRACK-HD study: Cross-sectional analysis of baseline data. Lancet Neurol, 2009; 8(9):791–801; doi: 10.1016/S1474-4422(09)70170-X
74.
DierksT, LindenDE, HertelA, et al.Multimodal imaging of residual function and compensatory resource allocation in cortical atrophy: A case study of parietal lobe function in a patient with Huntington’s disease. Psychiatry Res, 1999; 90(1):67–75.
75.
ThiruvadyDR, Georgiou-KaristianisN, EganGF, et al.Functional connectivity of the prefrontal cortex in Huntington’s disease. J Neurol Neurosurg Psychiatry, 2007; 78(2):127–133; doi: 10.1136/jnnp.2006.098368
76.
UnschuldPG, LiuX, ShanahanM, et al.Prefrontal executive function associated coupling relates to Huntington’s disease stage. Cortex, 2013; 49(10):2661–2673; doi: 10.1016/j.cortex.2013.05.015
RoussakisA-A, PicciniP. PET imaging in Huntington’s disease. J Huntingtons Dis, 2015; 4(4):287–296; doi: 10.3233/JHD-150171
79.
TurjanskiN, WeeksR, DolanR, et al.Striatal D1 and D2 receptor binding in patients with Huntington’s disease and other choreas. A PET study. Brain, 1995; 118 (Pt 3):689–696; doi: 10.1093/brain/118.3.689
80.
van OostromJCH, MaguireRP, Verschuuren-BemelmansCC, et al.Striatal dopamine D2 receptors, metabolism, and volume in preclinical Huntington disease. Neurology, 2005; 65(6):941–943; doi: 10.1212/01.wnl.0000176071.08694.cc
81.
GinovartN, LundinA, FardeL, et al.PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington’s disease. Brain, 1997; 120 (Pt 3):503–514; doi: 10.1093/brain/120.3.503
82.
BartensteinP, WeindlA, SpiegelS, et al.Central motor processing in Huntington’s disease. A PET study. Brain, 1997; 120 (Pt 9):1553–1567; doi: 10.1093/brain/120.9.1553
83.
CiarmielloA, CannellaM, LastoriaS, et al.Brain white-matter volume loss and glucose hypometabolism precede the clinical symptoms of Huntington’s disease. J Nucl Med, 2006; 47(2):215–222.
84.
RosasHD, TuchDS, HeveloneND, et al.Diffusion tensor imaging in presymptomatic and early Huntington’s disease: Selective white matter pathology and its relationship to clinical measures. Mov Disord, 2006; 21(9):1317–1325; doi: 10.1002/mds.20979
85.
DumasEM, van den BogaardSJA, RuberME, et al.Early changes in white matter pathways of the sensorimotor cortex in premanifest Huntington’s disease. Hum Brain Mapp, 2012; 33(1):203–212; doi: 10.1002/hbm.21205
86.
MorenaE, RomanoC, MarconiM, et al.Peripheral biomarkers in manifest and premanifest Huntington’s disease. Int J Mol Sci, 2023; 24(7):6051; doi: 10.3390/ijms24076051
87.
CaronNS, HaqqaniAS, SandhuA, et al.Cerebrospinal fluid biomarkers for assessing Huntington disease onset and severity. Brain Commun, 2022; 4(6):fcac309–f17; doi: 10.1093/braincomms/fcac309
88.
BlennowK, HampelH, WeinerM, et al.Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol, 2010; 6(3):131–144; doi: 10.1038/nrneurol.2010.4
89.
ShiM, BradnerJ, HancockAM, et al.Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol, 2011; 69(3):570–580; doi: 10.1002/ana.22311
90.
MillerTM, PestronkA, DavidW, et al.An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: A phase 1, randomised, first-in-man study. Lancet Neurol, 2013; 12(5):435–442; doi: 10.1016/S1474-4422(13)70061-9
91.
VonsattelJP, MyersRH, StevensTJ, et al.Neuropathological classification of Huntington’s disease. J Neuropathol Exp Neurol, 1985; 44(6):559–577; doi: 10.1097/00005072-198511000-00003
Moscovitch-LopatinM, GoodmanRE, EberlyS, et al.; Huntington Study Group PHAROS Investigators. HTRF analysis of soluble huntingtin in PHAROS PBMCs. Neurology, 2013; 81(13):1134–1140; doi: 10.1212/WNL.0b013e3182a55ede
94.
KhalilM, TeunissenCE, OttoM, et al.Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol, 2018; 14(10):577–589; doi: 10.1038/s41582-018-0058-z
95.
HoffmanPN, ClevelandDW, GriffinJW, et al.Neurofilament gene expression: A major determinant of axonal caliber. Proc Natl Acad Sci U S A, 1987; 84(10):3472–3476; doi: 10.1073/pnas.84.10.3472
96.
DiProsperoNA, ChenE-Y, CharlesV, et al.Early changes in Huntington’s disease patient brains involve alterations in cytoskeletal and synaptic elements. J Neurocytol, 2004; 33(5):517–533; doi: 10.1007/s11068-004-0514-8
97.
ConstantinescuR, RomerM, OakesD, et al.Levels of the light subunit of neurofilament triplet protein in cerebrospinal fluid in Huntington’s disease. Parkinsonism Relat Disord, 2009; 15(3):245–248; doi: 10.1016/j.parkreldis.2008.05.012
98.
NguyenL, BradshawJL, StoutJC, et al.Electrophysiological measures as potential biomarkers in Huntington’s disease: Review and future directions. Brain Res Rev, 2010; 64(1):177–194; doi: 10.1016/j.brainresrev.2010.03.004
99.
BylsmaFW, PeyserCE, FolsteinSE, et al.EEG power spectra in Huntington’s disease: Clinical and neuropsychological correlates. Neuropsychologia, 1994; 32(2):137–150; doi: 10.1016/0028-3932(94)90001-9
100.
OdishOFF, JohnsenK, van SomerenP, et al.EEG may serve as a biomarker in Huntington’s disease using machine learning automatic classification. Sci Rep, 2018; 8(1):16090; doi: 10.1038/s41598-018-34269-y
101.
LeuchterMK, DonzisEJ, CepedaC, et al.Quantitative electroencephalographic biomarkers in preclinical and human studies of Huntington’s disease: Are they fit-for-purpose for treatment development? Front Neurol, 2017; 8(MAR):91; doi: 10.3389/fneur.2017.00091
102.
MortonAJ, HowlandDS. Large genetic animal models of Huntington’s disease. J Huntingtons Dis, 2013; 2(1):3–19; doi: 10.3233/JHD-130050
103.
LiX-J, ChangR, LiuX, et al.Transgenic animal models for study of the pathogenesis of Huntington’s disease and therapy. Drug Des Devel Ther, 2015:2179; doi: 10.2147/DDDT.S58470
104.
HowlandDS, Munoz-SanjuanI. Mind the gap: Models in multiple species needed for therapeutic development in Huntington’s disease. Mov Disord, 2014; 29(11):1397–1403; doi: 10.1002/mds.26008
MenalledLB, KudwaAE, MillerS, et al.Comprehensive behavioral and molecular characterization of a new knock-in mouse model of Huntington’s disease: ZQ175. PLoS One, 2012; 7(12):e49838; doi: 10.1371/journal.pone.0049838
107.
HeikkinenT, LehtimäkiK, VartiainenN, et al.Characterization of neurophysiological and behavioral changes, MRI brain volumetry and 1H MRS in zQ175 knock-in mouse model of Huntington’s disease. PLoS One, 2012; 7(12):e50717; doi: 10.1371/journal.pone.0050717
108.
FisherSP, BlackSW, SchwartzMD, et al.Longitudinal analysis of the electroencephalogram and sleep phenotype in the R6/2 mouse model of Huntington’s disease. Brain, 2013; 136(Pt 7):2159–2172; doi: 10.1093/brain/awt132
109.
KantorS, SzaboL, VargaJ, et al.Progressive sleep and electroencephalogram changes in mice carrying the Huntington’s disease mutation. Brain, 2013; 136(Pt 7):2147–2158; doi: 10.1093/brain/awt128
110.
CallahanJW, AbercrombieED. Relationship between subthalamic nucleus neuronal activity and electrocorticogram is altered in the R6/2 mouse model of Huntington’s disease. J Physiol, 2015; 593(16):3727–3738; doi: 10.1113/JP270268
111.
MillerBR, WalkerAG, BartonSJ, et al.Dysregulated neuronal activity patterns implicate corticostriatal circuit dysfunction in multiple rodent models of Huntington’s disease. Front Syst Neurosci, 2011; 5:26; doi: 10.3389/fnsys.2011.00026
112.
MonteysAM, EbanksSA, KeiserMS, et al.CRISPR/Cas9 editing of the mutant Huntingtin allele in vitro and in vivo. Mol Ther, 2017; 25(1):12–23; doi: 10.1016/j.ymthe.2016.11.010
113.
MestreTA, SampaioC. Huntington disease: Linking pathogenesis to the development of experimental therapeutics. Curr Neurol Neurosci Rep, 2017; 17(2):18; doi: 10.1007/s11910-017-0711-8
114.
RinaldiC, WoodMJA. Antisense oligonucleotides: The next frontier for treatment of neurological disorders. Nat Rev Neurol, 2018; 14(1):9–21; doi: 10.1038/nrneurol.2017.148
115.
WeirDW, SturrockA, LeavittBR. Development of biomarkers for Huntington’s disease. Lancet Neurol, 2011; 10(6):573–590; doi: 10.1016/S1474-4422(11)70070-9
116.
BennettCF, BakerBF, PhamN, et al.Pharmacology of antisense drugs. Annu Rev Pharmacol Toxicol, 2017; 57(1):81–105; doi: 10.1146/annurev-pharmtox-010716-104846
117.
KeiserMS, KordasiewiczHB, McBrideJL. Gene suppression strategies for dominantly inherited neurodegenerative diseases: Lessons from Huntington’s disease and spinocerebellar ataxia. Hum Mol Genet, 2016; 25(R1):R53–R64; doi: 10.1093/hmg/ddv442
118.
KordasiewiczHB, StanekLM, WancewiczEV, et al.Sustained therapeutic reversal of Huntington’s disease by transient repression of huntingtin synthesis. Neuron, 2012; 74(6):1031–1044; doi: 10.1016/j.neuron.2012.05.009
119.
TabriziSJ, LeavittBR, LandwehrmeyerGB, et al.; Phase 1–2a IONIS-HTTRx Study Site Teams. Targeting huntingtin expression in patients with Huntington’s disease. N Engl J Med, 2019; 380(24):2307–2316; doi: 10.1056/NEJMoa1900907
120.
SmithAV, TabriziSJ. Therapeutic antisense targeting of huntingtin. DNA Cell Biol, 2020; 39(2):154–158; doi: 10.1089/dna.2019.5188
121.
DiFigliaM, Sena-EstevesM, ChaseK, et al.Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. Proc Natl Acad Sci U S A, 2007; 104(43):17204–17209; doi: 10.1073/pnas.0708285104
122.
FranichNR, FitzsimonsHL, FongDM, et al.AAV Vector–mediated RNAi of Mutant Huntingtin Expression Is Neuroprotective in a Novel Genetic Rat Model of Huntington’s Disease. Mol Ther, 2008; 16(5):947–956; doi: 10.1038/mt.2008.50
123.
MiniarikovaJ, ZanellaI, HuseinovicA, et al.Design, Characterization, and Lead Selection of Therapeutic miRNAs Targeting Huntingtin for Development of Gene Therapy for Huntington’s Disease. Mol Ther Nucleic Acids, 2016; 5(3):e297; doi: 10.1038/mtna.2016.7
124.
NasoMF, TomkowiczB, PerryWL, et al.Adeno-Associated Virus (AAV) as a Vector for Gene Therapy. BioDrugs, 2017; 31(4):317–334; doi: 10.1007/s40259-017-0234-5
125.
WildEJ, TabriziSJ. Therapies targeting DNA and RNA in Huntington’s disease. Lancet Neurol, 2017; 16(10):837–847; doi: 10.1016/S1474-4422(17)30280-6
126.
StanekLM, SardiSP, MastisB, et al.Silencing mutant huntingtin by adeno-associated virus-mediated RNA interference ameliorates disease manifestations in the YAC128 mouse model of Huntington’s disease. Hum Gene Ther, 2014; 25(5):461–474; doi: 10.1089/hum.2013.200
127.
GhilanM, BostromCA, HryciwBN, et al.YAC128 Huntington’s disease transgenic mice show enhanced short-term hippocampal synaptic plasticity early in the course of the disease. Brain Res, 2014; 1581:117–128; doi: 10.1016/j.brainres.2014.06.011
128.
AsaadM, HabibullahNK, ButlerCE. The impact of COVID-19 on clinical trials. Ann Surg, 2020; 272(3):e222–e223; doi: 10.1097/SLA.0000000000004113
129.
DabrowskaM, JuzwaW, KrzyzosiakWJ, et al.Precise excision of the CAG tract from the huntingtin gene by Cas9 nickases. Front Neurosci, 2018; 12:75; doi: 10.3389/fnins.2018.00075
130.
XuX, TayY, SimB, et al.Reversal of phenotypic abnormalities by CRISPR/Cas9-mediated gene correction in Huntington disease patient-derived induced pluripotent stem cells. Stem Cell Reports, 2017; 8(3):619–633; doi: 10.1016/j.stemcr.2017.01.022
131.
RunneH, KuhnA, WildEJ, et al.Analysis of potential transcriptomic biomarkers for Huntington’s disease in peripheral blood. Proc Natl Acad Sci U S A, 2007; 104(36):14424–14429; doi: 10.1073/pnas.0703652104
132.
LovrecicL, KastrinA, KobalJ, et al.Gene expression changes in blood as a putative biomarker for Huntington’s disease. Mov Disord, 2009; 24(15):2277–2281; doi: 10.1002/mds.22477
133.
WeissA, AbramowskiD, BibelM, et al.Single-step detection of mutant huntingtin in animal and human tissues: A bioassay for Huntington’s disease. Anal Biochem, 2009; 395(1):8–15; doi: 10.1016/j.ab.2009.08.001
134.
AtkinsonAJ, ColburnWA, DeGruttolaVG, et al.Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin Pharmacol Ther, 2001; 69(3):89–95; doi: 10.1067/mcp.2001.113989
135.
KotrcovaE, JarkovskaK, ValekovaI, et al.Challenges of Huntington’s disease and quest for therapeutic biomarkers. Proteomics Clin Appl, 2015; 9(1–2):147–158; doi: 10.1002/prca.201400073
136.
AzamHMH, RößlingRI, GeitheC, et al.MicroRNA biomarkers as next-generation diagnostic tools for neurodegenerative diseases: A comprehensive review. Front Mol Neurosci, 2024; 17:1386735; doi: 10.3389/fnmol.2024.1386735
